Edition:
United States

Bio Rad Laboratories Inc (BIO.N)

BIO.N on New York Stock Exchange

230.89USD
20 Sep 2017
Change (% chg)

$0.54 (+0.23%)
Prev Close
$230.35
Open
$230.84
Day's High
$231.40
Day's Low
$230.70
Volume
3,018
Avg. Vol
34,443
52-wk High
$242.58
52-wk Low
$154.89

Select another date:

Thu, Aug 31 2017

BRIEF-U.S. ITC to probe certain 10X Genomics devices after Bio-Rad complaint

* U.S. U.S. International Trade Commission says it will investigate certain microfluidic devices by 10x Genomics Inc after complaint by Bio-rad Laboratories Inc and Lawrence Livermore National Security LLC. Source text for Eikon: Further company coverage: (Reporting By Susan Heavey)

BRIEF-Bio-Rad reports Q2 earnings per share $0.17

* Q2 earnings per share view $0.56 -- Thomson Reuters I/B/E/S

Bio-Rad brings patent case against upstart rival 10X Genomics

The life sciences company Bio-Rad Laboratories Inc on Monday accused its upstart rival 10X Genomics of selling DNA analysis machines that infringe its patents.

BRIEF-Virbac signs a research agreement with Bio-Gene

* VIRBAC SA - VIRBAC SIGNS A RESEARCH AGREEMENT WITH BIO-GENE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Bio Rad Laboratories receives FDA clearance for Bioplex 2200 syphilis total & RPR assay​

* Bio Rad Laboratories Inc - ‍has received U.S. Food and Drug Administration clearance for its Bioplex 2200 syphilis total & RPR assay​ Source text for Eikon: Further company coverage:

BRIEF-Bio-Rad introduces enhanced options with its IH-COM data management software

* Bio-Rad introduces enhanced options with its IH-COM data management software for managing patient results with the IH-1000 system Source text for Eikon: Further company coverage:

BRIEF-Amicogen buys 9.1 pct stake in Bio-Works Technologies AB

* Says it has acquired 895,000 shares in Bio-Works Technologies AB, and is holding 9.1 percent stake in the co, from 0 percent stake

BRIEF-Autobio Diagnostics to invest in 75 pct stake in bio-tech firm Bio-top

* Says it plans to invest up to 202.5 million yuan ($29.32 million) for 75 percent stake in Beijing-based bio-tech firm Bio-top

BRIEF-Bio-Rad Laboratories reports Q1 earnings per share $0.41

* Q1 revenue $500.1 million versus I/B/E/S view $477.8 million

Fitch Affirms Bio-Rad's IDR at 'BBB-'; Outlook Stable

(The following statement was released by the rating agency) AUSTIN, April 05 (Fitch) Fitch Ratings has affirmed the ratings of Bio-Rad Laboratories, Inc. (Bio-Rad), including the 'BBB-' Issuer Default Rating (IDR). The ratings apply to approximately $437 million of debt at Dec. 31, 2016. The Rating Outlook is Stable. A full list of rating actions follows at the end of this release. KEY RATING DRIVERS Evolving Capital Allocation Strategy: Bio-Rad recently announced long-term targets for revenue g

Select another date: